Fezolinetant, sold under the brand name Veozah, was approved by the FDA on May 12, 2023.

Compugen has announced that the U.S. Food and Drug Administration has approved the investigational new drug application to begin a Phase 1 trial for COM503.

The FDA approved Arexvy on May 3, 2023. It is the first respiratory syncytial virus (RSV) vaccine approved for older adults.

Alpha Cognition has reported that the U.S. Food and Drug Administration has given the green light to ZUNVEYL® (benzgalantamine).

The FDA approved VOWST on April 26, 2023, for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI.

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia.

Yes, Tofersen, marketed under the brand name Qalsody, received FDA approval on April 25, 2023.

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer.

Omidubicel, marketed under the brand name Omisirge, is FDA approved. The FDA granted approval on April 17, 2023.

According to the agreement, Immunome has obtained exclusive rights to a collection of antibodies directed at an undisclosed target.

Vilobelimab, marketed under the brand name Gohibic, has been authorized by the FDA for emergency use but has not yet received full FDA approval for the treatment of COVID-19.

European Medicines Agency Rejects Eisai's Lecanemab for Alzheimer’s Treatment.